- Home
- PMM vs LUNG Comparison
PMM vs LUNG Comparison
Compare PMM & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMM
- LUNG
- Stock Information
- Founded
- PMM 1989
- LUNG 1995
- Country
- PMM United States
- LUNG United States
- Employees
- PMM N/A
- LUNG N/A
- Industry
- PMM Investment Managers
- LUNG Industrial Specialties
- Sector
- PMM Finance
- LUNG Health Care
- Exchange
- PMM Nasdaq
- LUNG Nasdaq
- Market Cap
- PMM 284.9M
- LUNG 299.3M
- IPO Year
- PMM N/A
- LUNG 2020
- Fundamental
- Price
- PMM $6.32
- LUNG $7.35
- Analyst Decision
- PMM
- LUNG Strong Buy
- Analyst Count
- PMM 0
- LUNG 7
- Target Price
- PMM N/A
- LUNG $12.64
- AVG Volume (30 Days)
- PMM 118.3K
- LUNG 284.5K
- Earning Date
- PMM 01-01-0001
- LUNG 04-30-2025
- Dividend Yield
- PMM 4.68%
- LUNG N/A
- EPS Growth
- PMM N/A
- LUNG N/A
- EPS
- PMM 0.23
- LUNG N/A
- Revenue
- PMM N/A
- LUNG $83,789,000.00
- Revenue This Year
- PMM N/A
- LUNG $17.96
- Revenue Next Year
- PMM N/A
- LUNG $18.35
- P/E Ratio
- PMM $26.52
- LUNG N/A
- Revenue Growth
- PMM N/A
- LUNG 22.01
- 52 Week Low
- PMM $5.00
- LUNG $5.46
- 52 Week High
- PMM $6.42
- LUNG $10.01
- Technical
- Relative Strength Index (RSI)
- PMM 60.43
- LUNG 46.66
- Support Level
- PMM $6.10
- LUNG $7.65
- Resistance Level
- PMM $6.44
- LUNG $7.97
- Average True Range (ATR)
- PMM 0.07
- LUNG 0.44
- MACD
- PMM 0.01
- LUNG -0.08
- Stochastic Oscillator
- PMM 65.29
- LUNG 33.04
About PMM Putnam Managed Municipal Income Trust
Putnam Managed Municipal Income Trust is a closed-end management investment company. Its investment objective is to seek a high level of current income exempt from federal income tax by investing in a diversified portfolio of tax-exempt municipal securities. The Fund invests in various sectors such as healthcare, retirement community, private higher education, housing-backed, essential service utilities, and state-backed bonds.
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.